Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European Journal of Clinical Microbiology and Infectious Diseases

• Publication date

  2012-08-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10096-012-1708-5PMID 23010902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Severe Community-acquired Pneumonia

  2012cited by this paper
• Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia

  2012cited by this paper
• Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia.

  2011cited by this paper
• Procalcitonin as a biomarker in respiratory tract infection.

  2011cited by this paper
• Ahlstrand E , Persson L , Tidefelt U , Söderquist B. Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy. Eur J Clin Microbiol Infect Dis

  2011cited by this paper
• British Thoracic Society adult community acquired pneumonia audit 2009/10

  2011cited by this paper
• Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community‐acquired pneumonia

  2011cited by this paper
• Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia.

  2011cited by this paper
• Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care.

  2010cited by this paper
• Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.

  2010cited by this paper
• Biomarkers in lower respiratory tract infections.

  2010cited by this paper
• Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey

  2010cited by this paper
• Clinical and economic burden of community-acquired pneumonia among adults in Europe

  2010cited by this paper
• Predicting mortality in patients with community-acquired pneumonia and low CURB-65 scores

  2010cited by this paper
• Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis

  2010cited by this paper
• Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia

  2010cited by this paper
• Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection

  2010cited by this paper
• Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia

  2010cited by this paper
• Neumonía adquirida en la comunidad. Nueva normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR)

  2010cited by this paper
• Use of Plasma Procalcitonin Levels as an Adjunct to Clinical Microbiology

  2010cited by this paper
• Biomarkers Improve Mortality Prediction by Prognostic Scales in Community-Acquired Pneumonia

  2010cited by this paper
• Viral Community-Acquired Pneumonia

  2010cited by this paper
• Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.

  2009cited by this paper
• Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia

  2009cited by this paper
• Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP – Results from the German competence network CAPNETZ

  2009influential reference
• Biomarkers and community-acquired pneumonia

  2009cited by this paper
• BTS guidelines for the management of community acquired pneumonia in adults: update 2009

  2009cited by this paper
• Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired Pneumonia

  2009cited by this paper
• Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes

  2008cited by this paper
• Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.

  2008cited by this paper
• Neumonía adquirida en la comunidad

  2007cited by this paper
• Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

  2007cited by this paper
• Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: A propensity-adjusted analysis.

  2007cited by this paper
• Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

  2006cited by this paper
• Procalcitonin and neopterin correlation with aetiology and severity of pneumonia.

  2006cited by this paper
• Development and validation of a clinical prediction rule for severe community-acquired pneumonia.

  2006cited by this paper
• Outpatient Care Compared With Hospitalization for Community-Acquired Pneumonia: A Randomized Trial in Low-Risk PatientsCarratalà J, Fernández-Sabé N, Ortega L, et al (Univ of Barcelona; SCIAS-Hosp de Barcelona) Ann Intern Med 142:165–172, 2005§

  2006cited by this paper
• Outpatient Care Compared with Hospitalization for Community-Acquired Pneumonia

  2005cited by this paper
• Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.

  2005cited by this paper
• Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults

  2005cited by this paper
• British Thoracic Society

  2004cited by this paper
• Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough.

  2004cited by this paper
• Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis.

  2004cited by this paper
• Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

  2003influential reference
• Neumonía adquirida en la comunidad

  2003cited by this paper
• A prediction rule to identify allocation of inpatient care in community-acquired pneumonia

  2003cited by this paper
• Clinical practice. Management of community-acquired pneumonia.

  2002cited by this paper
• DIAGNOSIS OF LEGIONELLA INFECTION

  2002cited by this paper
• Community-Acquired Pneumonia

  2002cited by this paper
• A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.

  2000cited by this paper
• Severe community-acquired pneumonia. Assessment of severity criteria.

  1998cited by this paper
• Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial.

  1998cited by this paper
• MEDICAL OUTCOMES AND ANTIMICROBIAL COSTS WITH THE USE OF THE AMERICAN THORACIC SOCIETY GUIDELINES FOR OUTPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA

  1997cited by this paper
• A prediction rule to identify low-risk patients with community-acquired pneumonia.

  1997cited by this paper
• Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.

  1997cited by this paper
• Metaphase and interphase fluorescence in situ hybridization mapping of the rice genome with bacterial artificial chromosomes.

  1995cited by this paper
• A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

  1983cited by this paper
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.

  1982cited by this paper

• Diagnostic value of procalcitonin for identifying the etiology of lower respiratory tract infections: a systematic review and meta-analysis

  2025cites this paper
• Improving prognostication of pneumonia among elderly patients: usefulness of suPAR

  2024cites this paper
• Biomarkers for risk stratification and antibiotic stewardship in elderly patients

  2023cites this paper
• Strategy for Procalcitonin-Controlled Antimicrobial Therapy in the COVID-19 Pandemic

  2022cites this paper
• Частота инфекционных осложнений и особенности системного воспалительного ответа у больных с длительным нарушением сознания

  2021cites this paper
• A literature review of severity scores for adults with influenza or community-acquired pneumonia – implications for influenza vaccines and therapeutics

  2021cites this paper
• Frequency of infectious complications and features of systemic inflammatory response in patients with prolonged disorders of consciousness

  2021cites this paper
• Where is Chlamydophila pneumoniae pneumonia?

  2020cites this paper
• Point-of-care testing for C-reactive protein in acute cough presentations in primary care

  2020cites this paper
• Relationship Between the Serum Level of C-Reactive Protein and Severity and Outcomes of Community-acquired Pneumonia

  2019cites this paper
• Blood circRNAs as biomarkers for the diagnosis of community‐acquired pneumonia

  2019cites this paper
• Comparison of procalcitonin, C-reactive protein, white blood cell count and clinical status in diagnosing pneumonia in patients hospitalized with acute exacerbations of COPD: A prospective observational study

  2018cites this paper
• Usefulness and prognostic value of biomarkers in patients with community-acquired pneumonia in the emergency department.

  2017cites this paper
• Identification of miRNA biomarkers of pneumonia using RNA-sequencing and bioinformatics analysis.

  2017cites this paper
• Utilidad y valor pronóstico de los biomarcadores en los pacientes con neumonía adquirida en la comunidad en los servicios de urgencias

  2017cites this paper
• Tools for outcome prediction in patients with community acquired pneumonia

  2017cites this paper
• Point-of-care testing for C-reactive protein in acute cough presentations

  2017cites this paper
• Procalcitonin levels correlates with the pathogeny and severity of community acquired pneumonia

  2016cites this paper
• The amino-terminal fragment of pro-brain natriuretic peptide in plasma as a biological marker for predicting mortality in community-acquired pneumonia: a cohort study

  2016cites this paper
• Community-Acquired Pneumonia 2000-2015: What is New?

  2016cites this paper
• Multimarker Prognostication for Hospitalized Patients with Community-acquired Pneumonia.

  2016influential citation
• The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study

  2016influential citation
• Host Biomarkers for Distinguishing Bacterial from Non-Bacterial Causes of Acute Febrile Illness: A Comprehensive Review

  2016cites this paper
• Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis

  2016cites this paper
• Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both?

  2015cites this paper
• Neumonía adquirida en la comunidad

  2015cites this paper
• Association of White Blood Cell Count and C-Reactive Protein with Outcomes in Children Hospitalized for Community-acquired Pneumonia

  2015cites this paper
• Community-acquired pneumonia.

  2015cites this paper
• [Ability of procalcitonin to predict bacteremia in patients with community acquired pneumonia].

  2014cites this paper
• Capacidad de la procalcitonina para predecir bacteriemia en pacientes con neumonía adquirida en la comunidad

  2014cites this paper
• Markers of lower respiratory tract infections in emergency departments

  2013cites this paper
• Major advances in managing community-acquired pneumonia

  2013cites this paper
• Management of community-acquired pneumonia

  2013cites this paper
• Clinical scoring tools: which is best to predict clinical response and long-term outcomes?

  2013cites this paper
• Clinical Scoring Tools

  year unknowncites this paper